CEO
Intensity Therapeutics
Westport, Connecticut, United States
Lewis H. Bender is the Founder, President and CEO of Intensity Therapeutics, a clinical stage biotechnology company pioneering a novel immune-based drug therapy approach to treat cancer. Lew led the Company from an idea to an on-going, international clinical trial at leading U.S. and Canadian academic hospitals. The Company has collaboration partnerships with the National Cancer Institute, Merck and Bristol Myers Squibb. FDA has designated the Company’s drug for FAST TRACK to treat triple negative breast cancer. Worldwide, patent and trademark Offices including the U.S. have granted the Company over 30 patents. Lew was selected by PharmaVOICE as one of the 100 most inspiring people in the life sciences in 2019. Her has raised over $27 million dollars to develop the novel cancer treatment concept.
Lew has over 28 years of biotech and pharmaceutical experience and has raised over $300 million in capital in his career. Prior to his founding of Intensity Therapeutics, Lew was the CEO of Interleukin Genetics, a personalized medicine company and held numerous executive positions at the drug delivery company Emisphere Technologies, Inc. including CEO. He is the author of dozens of articles on various business and scientific aspects of the pharmaceutical industry.
Lew has both a Bachelors and Masters of Science degree in Chemical Engineering from MIT, His MBA/MA degrees are from Wharton/Lauder programs from the class of 1993. Raised in the United States, Mr. Bender spent several years living in Switzerland and is fluent in French, German and probably has a 4+ score in the Swiss-German dialect from the Baselland area.